Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291901 · ClinicalTrials.gov registry record · Phase 2
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase 2 study of Neoplasms and Intractable Pain, sponsored by Diamyd.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 18
- Study locations
NCT01291901: Completed Phase 2 study of Neoplasms and Intractable Pain, sponsored by Diamyd.
NCT01291901 is a Phase 2 study of Neoplasms and Intractable Pain that has completed, run by Diamyd. The registered enrollment target is 33 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01291901, a Phase 2 study of Neoplasms and Intractable Pain, has completed, sponsored by Diamyd.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease. A second purpose is to confirm safety and secondary efficacy measurements.
Primary Outcome
• Change from baseline of the average daily NRS pain score (scale of 0 to 10 ) of Placebo compared to Active NP2 cohorts.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NP2
Study Locations (18)
California
- Compassionate Cancer Care Medical Group, Inc. - Corona
- Cancer Care Associates - Fresno
- TriWest Research Associates - La Mesa
- White Memorial Medical Center - Los Angeles
- Hematology Oncology Associates - Oakland
Arizona
- HOPE Research Institute - Phoenix
- Arizona Clinical Research Center - Tucson
Florida
- Advanced Pharma CR - Miami
Georgia
- Better Health Clinical Research Inc - Newnan
Illinois
- Christie Clinic - Champaign
Indiana
- Global Scientific Innovations - Evansville
Montana
- Montana Cancer Institute Foundation - Missoula
North Carolina
- Center for Clinical Research - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT01291901 record still lists
NCT01291901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01291901 lists 18 locations in 13 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT01291901 about?
NCT01291901 is a clinical study titled "NP2 Enkephalin For Treatment of Intractable Cancer Pain". The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease. A second purpose is to confirm safety and secondary efficacy measurements.
What is the current status of trial NCT01291901?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2011-01. Estimated completion is 2013-11.
What conditions does trial NCT01291901 study?
This clinical trial studies the following conditions: Neoplasms, Intractable Pain.
What interventions are being tested in trial NCT01291901?
The interventions under investigation include: Placebo (BIOLOGICAL), NP2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01291901?
This trial is sponsored by Diamyd, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01291901 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01291901's enrollment target sits among peer trials
33 129th of 158 higher than 27 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RECRUITING · Phase 2
-
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia